![James Hall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von James Hall
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Amplifier TX AB
![]() Amplifier TX AB BiotechnologyHealth Technology Part of Cambrian BioPharma, Inc., Amplifier TX AB is a Swedish biopharmaceutical company that develops clinical molecule AMPK activators. The private company is based in Umeå, Sweden. The company was founded in 2023 by Thomas Edlund, Helena Edlund. James Hall has been the CEO of the company since 2023. | Vorstandsvorsitzender | 14.03.2023 | - |
Karriereverlauf von James Hall
Statistik
International
Schweden | 3 |
Operativ
Chief Executive Officer | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Amplifier TX AB
![]() Amplifier TX AB BiotechnologyHealth Technology Part of Cambrian BioPharma, Inc., Amplifier TX AB is a Swedish biopharmaceutical company that develops clinical molecule AMPK activators. The private company is based in Umeå, Sweden. The company was founded in 2023 by Thomas Edlund, Helena Edlund. James Hall has been the CEO of the company since 2023. | Health Technology |
- Börse
- Insiders
- James Hall
- Erfahrung